RxDoctor Payments Data

Maria Elena de Benedetti Zunino, MD

Cardiovascular Disease · El Paso, TXNPI 1659686178

Payments from drug & device makers

$15,442in general payments, 2019–2025

Across 231 payments — averaging $66.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$7K
  • Impulse Dynamics (USA) Inc.$6K
  • Boston Scientific$916
  • Cvrx, Inc.$571
  • Novo Nordisk$251
  • Abbott$172
  • plus $893 from 9 others

What the payments were for

  • Consulting fees$4,61530%
  • Travel & lodging$1,3589%
  • Food & beverage$9,47061%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,442 in reported general payments places this provider in the 75th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$207,534
Medicare patients
376
Services billed
2,225

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban349$437,254
XareltoRivaroxaban118$138,506
BrilintaTicagrelor120$88,941
EntrestoSacubitril/Valsartan41$48,360
FarxigaDapagliflozin Propanediol37$43,697
OzempicSemaglutide19$24,675
Repatha SureclickEvolocumab31$23,009
JardianceEmpagliflozin12$14,263
Ranolazine ErRanolazine78$8,779
Metoprolol Succinate357$3,494
Midodrine Hcl34$3,254
Amiodarone Hcl82$2,131
ClopidogrelClopidogrel Bisulfate215$1,978
Amlodipine Besylate376$1,942
Losartan Potassium215$1,927

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBrilinta, Farxiga$121$132,639157 claims
NovartisEntresto$15$48,36041 claims
Novo NordiskOzempic$251$24,67519 claims
Boehringer IngelheimJardiance$46$14,26312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in El Paso

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →